Relevant bibliographies by topics / Drugs design

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Drugs design'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drugs design.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drugs design"

1

Bugg, Charles E., William M. Carson, and John A. Montgomery. "Drugs by Design." Scientific American 269, no. 6 (December 1993): 92–98. http://dx.doi.org/10.1038/scientificamerican1293-92.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

BORMAN, STU. "DRUGS BY DESIGN." Chemical & Engineering News Archive 83, no. 48 (November 28, 2005): 28–30. http://dx.doi.org/10.1021/cen-v083n048.p028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Krasnopolsky, Yu М. ""QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION." Biotechnologia Acta 13, no. 6 (December 2020): 5–12. http://dx.doi.org/10.15407/biotech13.06.005.

Full text
Abstract:
Nanobiotechnological preparations creation is one of the promising areas of modern pharmacy, since it allows creating products of a qualitatively new level. The procedure development, based on an understanding of the product characteristics and the technological process, confirmed by reliable scientific data. The article is devoted to the pharmaceutical development of liposomal drugs. On the basis of our own experience in the development of liposomal medicinal forms, as well as on the basis of literature data, the main components in their composition were detected and these components impact on the quality indicators of liposomes were studied. Individual lipids function in nanoparticle membrane and their interaction, which determines the stability both in the technological process and upon storage of the product, were considered. The advantages and disadvantages of cholesterol incorporation into liposomes with hydrophilic and hydrophobic active pharmaceutical ingredients were described. Cryoprotectors and buffer systems role in ensuring nanopreparation stability is discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Snyder, Solomon H. "Pharmacology: Virtuoso design of drugs." Nature 323, no. 6086 (September 1986): 292–93. http://dx.doi.org/10.1038/323292a0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Williams, Bryan R. G. "Design of anti-AIDS drugs." Virus Research 19, no. 1 (March 1991): 130. http://dx.doi.org/10.1016/0168-1702(91)90102-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

YOKOYAMA, MASAYUKI. "Molecular design of missile drugs." Kagaku To Seibutsu 26, no. 3 (1988): 199–202. http://dx.doi.org/10.1271/kagakutoseibutsu1962.26.199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ferriz, J. M., and J. Vinsova. "Prodrug Design of Phenolic Drugs." Current Pharmaceutical Design 16, no. 18 (June 1, 2010): 2033–52. http://dx.doi.org/10.2174/138161210791293042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Isnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal." Pharmaceutical Journal of Indonesia 6, no. 1 (December 1, 2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.

Full text
Abstract:
The main therapy on musculoskeletal patients is the use of non-steroidal anti-inflammatory drugs (NSAIDs) either as monotherapy or in combination with drugs of the same class or pain relievers from other groups. The use of more than one drugs have potentially caused drug-drug interactions that can affect to patient. This study was aimed to describe the patient's sociodemographic (sex, ages) and clinical (numbers of drugs, type of drugs and diagnose) characteristics, as well as to find the correlation between potential drug interactions with these variables. This research was a quantitative study with a cross sectional design. Data were taken from 100 medical records of patients who had diagnosed with top five musculoskeletal diseases. Data were analyzed descriptively for sex, ages, number of drugs, type of drugs, and potential drug interactions. Bivariate correlation with chi-square were conducted to find statistically significancy potential drug interactions with each variable consist of sex, ages, type of drugs and it’s diagnose. The result shows that the musculoskeletal patients were 44% male, 56% female. Most musculoskeletal patients were aged 18-65 years (78%). Patients who received drugs <5 were 68% and ≥ 5 were 32%. 54% of patients were taking the diclofenac and only 5% of patients were taking the two NSAIDs combination, diclofenac and ibuprofen. There was no significant correlation (p > 0,05) between potential drug interactions with age, sex, type of NSAID, and type of musculosceletal diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Carlson, Robert. "Supercomputers help design drugs super fast." Inpharma Weekly &NA;, no. 1155 (September 1998): 9–10. http://dx.doi.org/10.2165/00128413-199811550-00019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Korcsmáros, Tamás, Máté S. Szalay, Csaba Böde, István A. Kovács, and Péter Csermely. "How to design multi-target drugs." Expert Opinion on Drug Discovery 2, no. 6 (June 2007): 799–808. http://dx.doi.org/10.1517/17460441.2.6.799.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drugs design"

1

Attardo, Giorgio G. (Giorgio Giovanni). "Drug design and synthesis of novel heteroanthracycline antitumor drugs." Thesis, McGill University, 1990. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=74641.

Full text
Abstract:
Novel heteroanthracycline antitumor drugs were designed based on structure activity relationship studies and known mechanisms of drug action. Their preparation required the development of a general synthetic approach.
After extensive studies, three methodologies were developed for the general synthetic plan. The first method involved photoenolisation of 2,5-dimethoxybenzaldehyde and SO$ sb2$ entrapment of the o-quinodimethane to give 4,7-dimethoxy-1-hydroxy-1,3-dihydrobenzo(2,3-c) thiophene-2,2-dioxide. This compound served as a general intermediate towards the synthesis of several heteroanthracyclinones. It could be reduced to the oxathiin-2-oxide derivative which thermally extruded SO$ sb2$ to yield the o-quinodimethane. Reentrapment of this latter intermediate with various glyoxalates gave key isochroman derivatives. The second method is an improvement over the first. Isochromandiones with a C-1 hydroxyl functionality were prepared from oxidative demethylation of 1-hydroxyisochromans. These were obtained after acid hydrolysis of the coupling products between epoxides and the cuprate of 2,5-dimethoxy-6-methylbenzaldehydedioxane acetal. The third method involved a sequential cycloaddition routine with two o-quinodimethanes.
By combining newly developed techniques with known methods, a general synthetic plan was developed. Consequently, the total synthesis of six tetracyclic structural hybrids of the naphthoquinone(2,3-c) pyranyl class of antibiotics was accomplished; along with the total synthesis of (R) and (S) 1-(4$ sp prime$-O-p-nitrobenzoyl-N-trifluoroacetyldaunosamine)-$ 1,3$-dihydrothioxantho(2,3-c) thiophene-2,2-dioxide, p-nitrobenzyl(5,12-dihydroxy-3,4-dihydrothioxantho(2,3-c) and (3,2-c) pyran-3-yl)formate, and eight novel heteroanthracyclines with the 5,12-dioxo-2,3,5,12-tetrahydroanthraceno(2,3-c) pyranyl backbone. The diastereomeric mixture of (1$ sp prime$S, 1R, 3S) and (1$ sp prime$S, 1S, 3R) methyl(11-hydroxy-1-$(2 sp prime,3 sp prime,6 sp prime $-trideoxy-3-trifluoroacetamido-L-lyxohexopyranose)-$5,12 $-dioxo-3,4,5,12-tetrahydroanthraceno(2,3-c) pyran-3-yl) formate was found to possess equipotent antileukemic activity to doxorubicin with no cross resistance.
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Huarui. "Design, synthesis and activity evaluation of novel exosome inhibitors." HKBU Institutional Repository, 2020. https://repository.hkbu.edu.hk/etd_oa/849.

Full text
Abstract:
Background: Exosomes are extracellular vesicles (EVs) that produced in the endosomal compartment of most eukaryotic cells, and have observed increasing attentions over the past decades. They play important roles in cell- to-cell communications, they can carry varieties of substances, like proteins, nucleic acids and lipids, to the target cells they encounter. These cargos could influence the function of recipient cells. This novel mode of intercellular communication is found to be of critical importance to many cellular activities. However, exosomes are involved in various diseases processes. Tumor- derived exosomes could promote cancer progression, and our preliminary study indicated that exosome released from osteoclasts could inhibit bone formation. We also found that osteoarthritis (OA) progression in OA mice could be attenuated by inhibiting exosomes released by osteoclasts. Therefore, inhibition of exosome release has potential value in the treatment of diseases. The exosome release is under control by RAB27A, which is a protein involved in protein transport and signal transduction. It is reported that a compound named Nexinhib20 could selectively inhibit RAB27A, but this compound is highly toxic to RAW264.7 cells, which IC 50 is 1.5 µM. Therefore, for safety concerns, it has to be chemically modified to reduce toxicity. Aim: (1) To design and synthesize a series compounds based on the structure of Nexinhib20. (2) To evaluate the toxicity and exosome inhibiting activity of the synthesized compounds and discuss the structure-activity relationships (SAR) of them. Materials and Methods: Nexinhib20 derivatives were synthesized by aldol reaction. The cytotoxicity of these compounds was evaluated by MTT assay. The exosome inhibiting activity of these compounds was evaluated through exosome isolation and quantitation. Result: A series of compounds were synthesized and their structures were confirmed by LC-MS and NMR. The structure-activity relationships of these compounds were discussed, and the results showed that compounds A3, A23 and B2 exhibited lower toxicity compared to Nexinhib20 and strong exosome inhibiting ability. Conclusion: The results of this project indicate that A3, A23 and B2 exhibited low toxicity and good exosome inhibiting activity. Based on this, further chemical modification could be applied to develop new exosome inhibitors with better efficacy
APA, Harvard, Vancouver, ISO, and other styles
3

McCallum, Emma Clare. "Adaptive phase II clinical trial design using nonlinear dose-response models." Thesis, University of Cambridge, 2015. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.709013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ma, Haiqiu. "The formulation, manufacture and evaluation of capsules containing freeze-dried aqueous extracts of Leonotis Leonorus or Mentha Longifolia." Thesis, University of the Western Cape, 2006. http://etd.uwc.ac.za/index.php?module=etd&action=viewtitle&id=gen8Srv25Nme4_3777_1181559333.

Full text
Abstract:

Leonotis leonorus and Mentha longifolia are two herbs commonly used in South Africa, mostly in oral liquid dosage forms. Several disadvantages are associated with these traditional dosage forms which can perhaps be remedied by using an appropriate oral solid dosage form, provided the actual plant material in the latter still resemble, as closely as possible, the traditionally used material and provide products of suitable pharmaceutical quality. The objectives of this study were to prepare and evaluate the pharmaceutical suitability of the freeze-dried aqueous extracts of Leonotis Leonorus and Mentha Longifolia as plant raw material for the capsule dosage of these two therapies and to formulate and manufacture capsules of Leonotis Leonorus and Mentha Longifolia aqueous extract that would contain amounts of the plant materials equivalent to that found in their traditional liquid dosage forms, and have immediate release characteristics and suitability stability.

APA, Harvard, Vancouver, ISO, and other styles
5

Gustafsson, Jörgen. "Synthesis of cyclohexenedicarbaldehydes and studies of their biologic activity." Lund : Organic Chemistry 2, Lund Institute of Technology, University of Lund, 1994. http://books.google.com/books?id=ULpqAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Moorad, Razia. "Computer-aided drug design and the biological evaluation of anti-cancer drugs." Doctoral thesis, University of Cape Town, 2016. http://hdl.handle.net/11427/20715.

Full text
Abstract:
Computer-aided drug design has become a promising alternative to high-throughput screening by identifying potential hits in silico for in vitro evaluation. In this study a combination of ligand-based and structure-based virtual screening was performed to identify in silico hits. This was based on finding similar inhibitors to 6-amino-4-(4-phenoxyphenylethylamino) quinazoline, a potent inhibitor of the Nuclear Factor kappa B (NF-κB), a transcription factor that has a pivotal role in cancer survival and Pentamidine, an anti-parasitic drug that has recently been demonstrated to possess tumour-killing activity. A hierarchical methodology consisting of a similarity search followed by structure-based virtual screening of the ZINC database was performed. In order to perform the docking studies, binding sites for 6-amino-4-(4-phenoxyphenylethylamino) quinazoline on the NF-κB/IκBα complex were identified through blind docking. In addition, the National Cancer Institute (NCI) database was screened, utilising existing structure-activity relationship data from literature. A pharmacophore search was designed to test the hypothesis of the structural features necessary for activity as seen with quinazoline inhibitors of NF-κB. No virtual hits from the ZINC database were confirmed with in vitro activity. On the other hand, three compounds identified from the pharmacophore search were confirmed to inhibit cancer cell proliferation in vitro, with compound NSC727152 demonstrating the most potent activity. In order to determine if NSC727152 acted similarly to 6-amino-4-(4-phenoxyphenylethylamino) quinazoline by inhibiting NF-κB, the effects of NSC727152 on the expression of NF-κB targeted genes, including the Growth Arrest and DNA Damage 45 (GADD45) α and γ and the Interleukin 6 (IL-6) genes were evaluated. GADD45 α and γ have been shown to be regulated by NF-κB during cancer progression and aberrant IL-6 gene expression has been implicated in cancer progression and mortality and its expression is at least partially mediated via constitutive activation of NF-κB. In this study, it has been demonstrated that GADD45 α and γ are upregulated after treatment with NSC727152. A down-regulation of the IL-6 promoter activity and mRNA expression in cancer cells treated with NSC727152 has also been demonstrated in this study. However, no hits similar to Pentamidine were confirmed with in vitro activity. In conclusion, the compound NSC727152 has been shown to inhibit NF-κB and further analysis is necessary to determine its full potential as an NF-κB inhibitor.
APA, Harvard, Vancouver, ISO, and other styles
7

IACUZZI, VALENTINA. "Design of detection systems for the therapeutic drug monitoring of anticancer drugs." Doctoral thesis, Università degli Studi di Trieste, 2020. http://hdl.handle.net/11368/2967986.

Full text
Abstract:
Considerato che la maggior parte dei farmaci antitumorali risulta caratterizzata da un'alta variabilità interindividuale nelle concentrazioni plasmatiche, che si riflette sull'efficacia del trattamento, durante il progetto di dottorato qui descritto sono state sviluppate tecniche per il loro monitoraggio terapeutico (TDM). In primo luogo, è stato sviluppato, validato e cross-validato un metodo LC-MS/MS per la quantificazione di imatinib (IMA) e del suo metabolita attivo, norimatinib (norIMA), in pazienti affetti da tumore stromale gastrointestinale utilizzando la tecnica del dried blood spot (DBS). Il DBS consente di ridurre costi e tempi di campionamento e migliorare la compliance dei pazienti, poiché l’analisi viene effettuata tramite una goccia di sangue capillare depositata su carta. Da questa gli analiti vengono estratti con MeOH acidificato e l'estratto viene iniettato in un sistema LC (configurato con una cromatografia 2D per la pulizia on-line del campione), accoppiato ad un API-4000QT. Il metodo ha mostrato una buona linearità (R2> 0,996) nei range di 50-7500 ng/mL e 10-1500 ng/mL per IMA e norIMA. La precisione e l’accuratezza intra-day sono state, rispettivamente, ≤3.1% e tra 88.9-112.8%, mentre quelle inter-day erano ≤6,6% e tra 95.7-104.3%, per entrambi gli analiti. Sono stati valutati inoltre: l'influenza dell'ematocrito (Hct), del volume depositato e dell'omogeneità del campione sull’analisi; la correlazione tra la concentrazione in DBS da prelievo venoso e da finger-prick (differenza tra -12 e 3.8%) e la stabilità dei DBSs (fino a 16 mesi). Il metodo è stato applicato per la quantificazione di 67 campioni DBSs di pazienti. Le concentrazioni in DBS, normalizzate per Hct e per un fattore di correzione che prescinde dall’Hct, correlano con quelle plasmatiche. Parte del lavoro di questo progetto è stato anche dedicato allo sviluppo di strategie alternative a LC-MS/MS per favorire ulteriormente l’applicazione del TDM. In particolare, è stata eseguita la sintesi di polimeri (molecularly imprinted polymers - MIPs), con l'obiettivo futuro di applicarli come recettori in un sistema di rilevamento fluorimetrico per IMA. I MIPs sono stati sintetizzati sfruttando l'approccio non covalente e la polimerizzazione radicale ad alta diluizione. Tramite questa tecnica, i MIPs ottenuti, sintetizzati in DMSO e con acido metacrilico come monomero funzionale, presentano dimensioni nanometriche (dati acquisiti tramite dynamic light scattering). I tests di rebinding hanno dimostrato che solo 2 MIPs sono stati in grado di legare IMA con una buona specificità (rispetto ai corrispondenti polimeri non-imprinted) e selettività. È stato infine sviluppato e validato un metodo LC-MS/MS per la quantificazione di ribociclib (RIBO), palbociclib (PALBO) e letrozolo (LETRO) in plasma. RIBO e PALBO sono farmaci appartenenti alla famiglia dei CDKIs recentemente approvati per il trattamento del carcinoma mammario in combinazione con LETRO. Il metodo messo a punto risulta adatto per l’applicazione nella pratica clinica, grazie ad una semplice preparazione del campione e ad una rapida analisi (6.5 min). Il metodo risulta lineare (R2 tra 0.992-0.983) nei range di concentrazione di 0.3-250 ng/mL per PALBO, 10-10000 ng/mL per RIBO e 0.5-500 ng/mL per LETRO (che coprono le concentrazioni plasmatiche terapeutiche). La precisione e l’accuratezza intra-day sono state, rispettivamente, ≤3.6% e tra 94.5-112.3% per tutti e gli analiti, mentre quelle inter-day erano rispettivamente ≤7.3% e tra 94.5-112.9%. Il metodo è stato applicato con successo alla quantificazione di campioni plasmatici di pazienti. In conclusione, con lo sviluppo di queste strategie si spera di implementare l’utilizzo del TDM per i farmaci oncologici nella pratica clinica.
Despite the continuous progress in drug therapy, most anticancer drugs appear to be characterized by a high interindividual variability in plasma concentrations that is reflected in the efficacy of the treatment. From this arises the need of a personalized approach, so that the drug concentrations in plasma are adequate in each patient. On this basis, during the PhD project reported hereby, different techniques for therapeutic monitoring (TDM) of anticancer drugs were developed. First, a LC-MS/MS method for the quantification of imatinib (IMA) and its active metabolite, norimatinib (norIMA), was developed, validated and cross-validated in patients affected by gastrointestinal stromal tumour. This method allows to perform the quantification directly on a drop of capillary blood, exploiting the dried blood spot (DBS) technique, reducing sampling time, costs and improving patients’ compliance. Analytes were extracted from DBS samples by adding acidified methanol and the extract is injected into a LC system (configured with a 2D chromatography for online cleaning of the sample), coupled with an API-4000QT. The method showed good linearity (R2> 0.996) in the ranges of 50-7500 ng/mL and 10-1500 ng/mL for IMA and norIMA. Intra-day precision and accuracy were ≤3.1% and between 88.9-112.8%, respectively, while inter-day ones were ≤6.6% and between 95.7-104.3 %, for both analytes. Moreover, were also evaluated: the influence of the haematocrit (Hct), of the spot size and of the sample homogeneity on the analysis; the correlation between the concentration in DBS from venous sampling and from finger-prick (% difference between -12 and 3.8%) and the stability of DBSs (up to 16 months). Then, the method was applied for the quantification of 67 DBSs patients’ samples. Good agreement was obtained between IMA and norIMA concentrations found in DBS and plasma samples applying either the Hct normalization or avoiding it, simply multiplying the DBS concentration with a correction factor. Part of the work of this project was also dedicated for the development of alternative strategies for the quantification of anticancer drugs, to promote the application of TDM. In particular, the synthesis of molecularly imprinted polymers (MIPs) was performed, with the future goal of applying them as receptors in a fluorimetric detection system for IMA. MIPs were synthesized using the non-covalent approach and high dilution radical polymerization. Through this synthesis, the MIPs obtained, synthesized in DMSO with methacrylic acid as functional monomer, shown nanometric size (data acquired by dynamic light scattering). The rebinding tests then showed that 2 MIPs in particular were able to bind IMA with a good specificity (compared to the corresponding non-imprinted polymers) and selectivity. Finally, a LC-MS/MS method was developed and validated for the quantification of ribociclib (RIBO), palbociclib (PALBO) and letrozole (LETRO) in human plasma. RIBO and PALBO are drugs belonging to the CDKIs family, recently approved for breast cancer treatment in combination with LETRO. The method developed is suitable for its application in clinical practice, thanks to simple sample preparation and rapid analysis (6.5 min). The method showed a good linearity (R2 between 0.992-0.983) in the concentration ranges of 0.3-250 ng/mL for PALBO, 10-10000 ng mL for RIBO and 0.5-500 ng/mL for LETRO (covering the therapeutic plasma concentrations). Intra-day precision and accuracy were ≤3.6% and between 94.5-112.3% for all and analytes, respectively, while inter-day ones were ≤ 7.3% and 94.5-112.9%. The method has been successfully applied for patients’ plasma samples quantification. In conclusion, with the development of these strategies there is the hope to implement the application of TDM for anticancer drugs in the clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
8

Gupta, Sona. "Rational design and delivery of peptide drugs." Thesis, Bangor University, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.323850.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Soldevila, Barreda Joan Josep. "Design of catalytic organometallic anti-cancer drugs." Thesis, University of Warwick, 2014. http://wrap.warwick.ac.uk/63808/.

Full text
Abstract:
This thesis is concerned with the design of organometallic half sandwich complexes which can catalyse the conversion of oxidised coenzyme nicotinamide adenine dinucleotide to its reduced form. The coenzyme pair NAD+/NADH is involved in many biological processes, such as regulation of the redox balance, and DNA repair. Disturbance of the NAD+/NADH ratio can lead to cell death. In particular, cancer cells are under constant oxidative stress and therefore might be more susceptible to changes in the NAD+/NADH levels. A series of neutral Ru(II) complexes of the type [(η6-arene)Ru(N,N’)(L)] (arene = p-cymene (p-cym), hexamethylbenzene (hmb), biphenyl (bip), benzene (bn); N,N’ = N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide (TfEn), N-(2-aminoethyl)-toluensulfonamide (TsEn), or N-(2-aminoethyl)-4-methylensulfonamide (MsEn)) were synthesized and fully characterized. The complexes were shown by 1H-NMR to catalyse region-selectively the transfer hydrogenation of NAD+ to 1,4-NADH. Comparison of the turnover frequencies (TOF) for the complexes show a trend in which a decrease in catalytic activity with the arene ligand follows the order bn > bip > p-cym > hmb and TfEn > TsEn > MsEn. Complex [(η6-bn)Ru(TfEn)Cl] (12) was found to be the most active with a TOF of 10.4 h-1. The catalytic cycle for the transfer hydrogenation reaction was studied for complex [(p-cym)Ru(TsEn)Cl] (2). The monotosylate ethylenediamine Ru(II) complexes were used to carry out, for the first time, transfer hydrogenation reactions in cellulo (A2780 ovarian cancer cells) using formate as a hydride source. The antiproliferative activity of six complexes on co-administration with non-toxic doses of sodium formate were studied. A significant potentiation of the antiproliferative activity by formate was observed. The concentrations of NAD+ and NADH in cells showed an important reduction in the NAD+/NADH ratio. This study demonstrates that it may be possible to use catalytic transfer hydrogenation as a strategy for multi-targeted redox mechanisms of action for anticancer drugs. In order to compare the anticancer mechanism of the monotosylate ethylenediamine Ru(II) complexes with the corresponding ethylenediamine (en) complexes, DNA binding studies were carried out. The complexes were shown to bind to nucleobases only moderately strongly and no direct coordination to calf thymus DNA was observed. The complexes can destabilize DNA, but they display low affinity towards DNA, which suggests that DNA is probably not involved in the mechanism of these family of compounds. Interaction of complex [(p-cym)Ru(TsEn)] (2) with glutathione (GSH) was also studied. The complex undergoes ligand substitution. Two Ru(II) dimers were formed as the main products of the reaction: ([((p-cym)Ru)2(μ-GS)3] and [((p-cym)Ru)2(μ-GS)2]). These dimers share structural similitudes with other reported Ru(II) arene anticancer drugs, which suggests that they could be responsible for the moderate antiproliferactive activity of complex 2. A series of CpxRh(III) (CpX = CpXPhPh, CpXPh or Cp*) complexes containing en or TfEn were synthesised and fully characterised. The complexes were shown to catalyse regioselectively the transfer hydrogenation of NAD+ to 1,4-NADH with higher TOF than their Ru(II) analogues. Rh(III)-en compounds were shown to be more active than the Rh(III)-TfEn analogues. The nature of the Cpx ring was shown to influence significantly the catalytic activity of the complexes following the trend: CpXPhPh > CpXPh > Cp*. Complex [(CpXPhPh)Rh(en)Cl]+ (19) was the most active, with a TOF of 24.2 h-1. The catalytic cycle for the transfer hydrogenation reaction was studied using complex [(Cp*)Rh(en)Cl]+ (17) and compared to that of the Ru(II) analogues, and was found to be similar. Antiproliferative activity of the complexes in combination with formate, in A2780 cells, was investigated, but the potentiation due to the transfer hydrogenation was much lower than that obtained with Ru(II) compounds.
APA, Harvard, Vancouver, ISO, and other styles
10

Tripathi, Ashutosh. "DEVELOPMENT OF HINT BASED COMPUTATIONAL TOOLS FOR DRUG DESIGN: APPLICATIONS IN THE DESIGN AND DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS." VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1866.

Full text
Abstract:
The overall aim of the research is to develop a computational platform based on HINT paradigm for manipulating, predicting and analyzing biomacromolecular-ligand structure. A second synergistic goal is to apply the above methodology to design novel and potent anti-cancer agents. The crucial role of the microtubule in cell division has identified tubulin as an interesting target for the development of therapeutics for cancer. Pyrrole-containing molecules derived from nature have proven to be particularly useful as lead compounds for drug development. We have designed and developed a series of substituted pyrroles that inhibit growth and promote death of breast tumor cells at nM and μM concentrations in human breast tumor cell lines. In another project, stilbene analogs were designed and developed as microtubule depolymerizing agents that showed anti-leukemic activity. A molecular modeling study was carried out to accurately represent the complex structure and the binding mode of a new class of tubulin inhibitors that bind at the αβ-tubulin colchicine site. These studies coupled with HINT interaction analyses were able to describe the complex structure and the binding modes of inhibitors. Qualitative analyses of the results showed general agreement with the experimental in vitro biological activity for these derivatives. Consequently, we have been designing new analogs that can be synthesized and tested; we believe that these molecules will be highly selective against cancer cells with minimal toxicity to the host tissue. Another goal of our research is to develop computational tools for drug design. The development and implementation of a novel cavity detection algorithm is also reported and discussed. The algorithm named VICE (Vectorial Identification of Cavity Extents) utilizes HINT toolkit functions to identify and delineate a binding pocket in a protein. The program is based on geometric criteria and applies simple integer grid maps to delineate binding sites. The algorithm was extensively tested on a diverse set of proteins and detects binding pockets of different shapes and sizes. The study also implemented the computational titration algorithm to understand the complexity of ligand binding and protonation state in the active site of HIV-1 protease. The Computational titration algorithm is a powerful tool for understanding ligand binding in a complex biochemical environment and allows generating hypothesis on the best model for binding.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Drugs design"

1

Povl, Krogsgaard-Larsen, Liljefors Tommy, and Madsen Ulf, eds. A Textbook of drug design and development. 2nd ed. Australia: Harwood Academic Publishers, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klesov, A. A. Glycobiology and drug design. Edited by American Chemical Society. Division of Carbohydrate Chemistry. Washington DC: American Chemical Society, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Povl, Krogsgaard-Larsen, Strømgaard Kristian, and Madsen Ulf, eds. Textbook of drug design and discovery. 4th ed. Boca Raton: CRC Press/Taylor & Francis, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Klesov, A. A. Glycobiology and drug design. Edited by American Chemical Society. Division of Carbohydrate Chemistry. Washington DC: American Chemical Society, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Williams, Robert O., Alan B. Watts, and Dave A. Miller. Formulating poorly water soluble drugs. New York, NY: AAPS Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fernández, Ariel. Transformative concepts for drug design: Target wrapping. Berlin: Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ward, David J., B.Sc., ed. Peptide pharmaceuticals: Approaches to the design of novel drugs. Milton Keynes: Open University Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

B, Weiner David, and Williams William V, eds. Biological approaches to rational drug design. Boca Raton: CRC Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Edgar, Kevin J., Charles M. Buchanan, and Thomas Heinze. Polysaccharide materials: Performance by design. Washington DC: American Chemical Society, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

M, Ottenbrite Raphael, and Kim Sung Wan, eds. Polymeric drugs & drug delivery systems. Lancaster, Pa: Technomic Pub. Co., 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Drugs design"

1

Folkers, Gerd, Elvan Kut, and Martin Boyer. "Drug Design: Designer Drugs." In X.media.publishing, 53–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-69002-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klebe, Gerhard. "How Drugs Act: Concepts for Therapy." In Drug Design, 471–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-17907-5_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Yuxuan, and Ross D. King. "Extrapolation is Not the Same as Interpolation." In Discovery Science, 277–92. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-45275-8_19.

Full text
Abstract:
AbstractWe propose a new machine learning formulation designed specifically for extrapolation. The textbook way to apply machine learning to drug design is to learn a univariate function that when a drug (structure) is input, the function outputs a real number (the activity): F(drug) → activity. The PubMed server lists around twenty thousand papers doing this. However, experience in real-world drug design suggests that this formulation of the drug design problem is not quite correct. Specifically, what one is really interested in is extrapolation: predicting the activity of new drugs with higher activity than any existing ones. Our new formulation for extrapolation is based around learning a bivariate function that predicts the difference in activities of two drugs: F(drug1, drug2) → signed difference in activity. This formulation is general and potentially suitable for problems to find samples with target values beyond the target value range of the training set. We applied the formulation to work with support vector machines (SVMs), random forests (RFs), and Gradient Boosting Machines (XGBs). We compared the formulation with standard regression on thousands of drug design datasets, and hundreds of gene expression datasets. The test set extrapolation metrics use the concept of classification metrics to count the identification of extraordinary examples (with greater values than the training set), and top-performing examples (within the top 10% of the whole dataset). On these metrics our pairwise formulation vastly outperformed standard regression for SVMs, RFs, and XGBs. We expect this success to extrapolate to other extrapolation problems.
APA, Harvard, Vancouver, ISO, and other styles
4

Klebe, Gerhard. "Biologicals: Peptides, Proteins, Nucleotides, and Macrolides as Drugs." In Drug Design, 813–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-17907-5_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nguyen, Jeffrey-Tri, and Yoshiaki Kiso. "Delivery of Peptide Drugs." In Peptide Chemistry and Drug Design, 271–310. Hoboken, NJ, USA: John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118995303.ch8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Colman, P. M. "Drugs Targeting Influenza Virus Neuraminidase." In Structure-Based Drug Design, 87–93. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-015-9028-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Workman, Paul. "Design of Novel Bioreductive Drugs." In New Approaches in Cancer Pharmacology: Drug Design and Development, 63–74. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77874-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fischman, A. J., R. H. Rubin, and H. W. Strauss. "In Vivo Imaging in Drug Discovery and Design." In Pharmacokinetics of Drugs, 481–503. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78680-8_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Adams, Jerry L., Paul Bamborough, David H. Drewry, and Lisa Shewchuk. "Strategies for Discovering Kinase Drugs." In Gene Family Targeted Molecular Design, 119–57. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2008. http://dx.doi.org/10.1002/9780470423936.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jacobs, Terry. "Chapter 4 Architectural Design Issues." In Drugs and the Pharmaceutical Sciences, 89–124. 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742: CRC Press, 2016. http://dx.doi.org/10.1201/9781315372242-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drugs design"

1

Rautiola, Davin, and Ronald A. Siegel. "Nasal Spray Device for Administration of Two-Part Drug Formulations." In 2019 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/dmd2019-3216.

Full text
Abstract:
Intranasal drug delivery is an attractive route to noninvasively achieve a rapid therapeutic effect, avoid first pass metabolism, and bypass the blood brain barrier. However, the types of drugs that can be administered by this route has been limited, in part, by device technology. Herein, we describe a pneumatic nasal spray device that is capable of mixing liquid and solid components of a drug formulation as part of the actuation process during dose administration. The ability to store a nasal spray drug formulation as two separate components can be leveraged to solve a variety of stability issues that would otherwise preclude intranasal administration. Examples of drugs that could be delivered intranasally by utilizing this two-part formulation strategy include biomolecules that are unstable in solution and low solubility drugs that can be rendered into metastable supersaturated solutions. A proof of concept nasal spray device prototype was constructed to demonstrate that a liquid and solid can be rapidly mixed and atomized into a spray in a single action. The primary breakup distance and angle of the spray cone were measured as a function of the function of the propellant gas pressure.
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Jae-Hwan, and Ramana M. Pidaparti. "An Implantable Device Design Concept for Ocular Drug Delivery." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80176.

Full text
Abstract:
New drugs for curing eye diseases have been developing for a decade and are very unique for each eye diseases such as glaucoma, cataracts, and age-related macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the age of 50 and above suffer from age-related macular degeneration and about 200,000 cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually [1]. Drugs currently utilized for AMD are delivered via repeated intravitreal injections of the drug into the eye. Risks of repeated intravitreal injections can include intraocular infections (endophthalmitis), intraocular hemorrhage, and retinal detachment. Also, reducing the frequency of dosing will clearly benefit the patient by reducing the need for risky intravitreal injections and improving the pharmacokinetics of the drug in the eye. The eye disease of posterior segment (Dry and Wet) has limits to deliver the drug to retina region using typical eye drop. The drug injection using a needle with syringe can deliver but it barely provide right amount of doses, or over doses that may cause more severe problem such as swelling, fatigue, and damaging photoreceptor molecules. Furthermore, most drugs run away in a month so that repeated injection is necessary. Developing an implantable drug delivery device will help reduce the costs and risks associated with frequent injections and facilitate delivering the drug in a controlled manner and in the required amounts, and improve therapeutic efficacy and safety of drugs. This study focuses on the design, simulation and development of the implantable ocular drug delivery device.
APA, Harvard, Vancouver, ISO, and other styles
3

Groeneveld, Patrick, Rob A. Rutenbar, Jed Pitera, Erik Carlson, and Jinsong Chen. "Oil fields, hedge funds, and drugs." In the 46th Annual Design Automation Conference. New York, New York, USA: ACM Press, 2009. http://dx.doi.org/10.1145/1629911.1630021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mendes, Pedro J., Joa˜o M. M. Sousa, and Joa˜o F. Pinto. "A Virtual Apparatus for Design and Testing of New Drug Formulations and Devices for Inhalation Therapy." In ASME 2007 2nd Frontiers in Biomedical Devices Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/biomed2007-38027.

Full text
Abstract:
Delivery of drugs to the lungs as aerosols is regarded as an excellent route for local or systemic administration of drugs. Aerosols have been used traditionally for treating illnesses of the respiratory tract (e.g. asthma), but new perspectives and needs on inhalation therapy have recently emerged (e.g. insulin). The percentage of drug that reaches the targeted region, the so-called respirable fraction (RF), is in average only 30% of the dose provided to the patient. Thus, the development of more efficient formulations and devices remains an important issue.
APA, Harvard, Vancouver, ISO, and other styles
5

Dolla, William Jacob S., Brian A. Fricke, and Bryan R. Becker. "Auxetic Drug-Eluting Stent Design." In ASME 2006 Frontiers in Biomedical Devices Conference. ASMEDC, 2006. http://dx.doi.org/10.1115/nanobio2006-18035.

Full text
Abstract:
A cardiovascular stent is a cylindrical wire mesh structure that is permanently introduced into an artery during angioplasty (balloon dilatation) to act as a scaffold, thus preventing elastic recoil and/or sudden collapse of the damaged artery. While cardiovascular stents virtually eliminate elastic recoil and/or collapse of the artery, recognition of the stent as a foreign material triggers a human immune system response causing re-closure, or restenosis, of the artery. A recent advancement to counteract restenosis is to employ drug-eluting stents to locally deliver immunosuppressant and antiproliferative drugs.
APA, Harvard, Vancouver, ISO, and other styles
6

Chebrolu, Anika. "DeepLig: A De-Novo Computational Drug Design Approach to Generate Multi-Targeted Drugs." In 2023 Fifth International Conference on Transdisciplinary AI (TransAI). IEEE, 2023. http://dx.doi.org/10.1109/transai60598.2023.00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Liu, Miao, and Wenjun Wang. "Analysis of antibiotic purchasing service design based on SAPAD-AHP method." In 13th International Conference on Applied Human Factors and Ergonomics (AHFE 2022). AHFE International, 2022. http://dx.doi.org/10.54941/ahfe1002124.

Full text
Abstract:
In the medical field, more than half of people will choose antibiotics for self-medication, they believe that antibiotics can be used for illnesses such as colds and fevers, or even for viral infections, which accelerates bacterial immunity to antibiotics. Misuse of antibiotics is not only unhelpful, but can damage the organism in a variety of ways that can lead to drug resistance, drug toxicity and allergic reactions. Worldwide, hundreds of thousands of people die each year due to bacterial resistance. In China, the use of antibiotics is even higher in outpatient and inpatient settings. The misuse of antibiotics poses a serious threat to the effectiveness of their use. In order to raise awareness of the dangers of antibiotic misuse, reduce people's choice of non-essential antibiotic medication, and expand and improve monitoring of health care institutions, this study introduces the SAPAD model and AHP to tap into users' real needs and complete a study of users' service design system for antibiotic drug purchase.The article uses observation method, user interview method and questionnaire method in the early stage to get the process of users' medicine purchase in common flu. Based on the SAPAD model framework, the user behavior is disassembled, and the people and things involved in the drug purchase process are listed to complete the mapping of behavior-object-meaning. The study obtained meaning clusters by clustering analysis of meaning layers, and combined with AHP to calculate the weight of each meaning cluster to derive core meaning clusters. The SAPAD model is a user-centered model framework for solving practical problems, which can start from the user's behavior, analyze, cluster and reorganize the meaning behind the behavior layer by layer, and finally dig into the user's real needs; the AHP method combines qualitative and quantitative analysis, and is highly logical and scientific, which can be applied to this topic The effective combination of SAPAD model and hierarchical analysis can gradually quantify the qualitative analysis and obtain more objective research results, which provides new ideas for the theoretical research framework of service design.This study completes the construction of meaning-based objects through the mapping of core meaning clusters to objects. The research process analyzes the key behaviors of users in purchasing drugs in common influenza, and obtains four semantic level meaning clusters through cluster analysis, namely "want to buy drugs quickly and correctly", "want to fully understand the effects of drugs", "want doctors to provide advice on appropriate medication" and "want to raise awareness of antibiotic medications". The study used AHP to analyze the meaning clusters and calculated the weights of each level to obtain the core meaning clusters of "buy the right medicine quickly", "get the right medication diagnosis", and "understand the effect of the medicine".The study reconstructed the service design system for users to purchase drugs in the process of common influenza through user requirements, summarized the key design elements, and improved the service function modules of online drug purchase and online consultation and advice.This study combines SAPAD model and AHP to design research on the user's antibiotic purchase process. Through the SAPAD model, we deeply study the user behavior, get the mapping of user behavior and meaning, and combine the quantitative research of AHP to get the core meaning cluster "quickly buy the right medicine", "get the right diagnosis of medication" and "understand the effect of medication", which guide the design of the service system of user's medication purchase process and the design of the APP for online medication purchase consultation. The SAPAD-AHP method in this study improved the function of the service system for antibiotic purchase process, and the designed output APP effectively improved the user's knowledge on the cautious use of antibiotics, strengthened the supervision of doctors' prescribing of antibiotics, and provided an effective solution to improve the problem of excessive use of antibacterial drugs in primary care institutions and rural areas.
APA, Harvard, Vancouver, ISO, and other styles
8

Feng, Yu, Xiaole Chen, and Mingshi Yang. "An In Silico Investigation of a Lobe-Specific Targeted Pulmonary Drug Delivery Method." In 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6928.

Full text
Abstract:
Nowadays, “personalized medicine” is starting to replace the current “one size fits all” approach. The goal is to have the right drug with the right dose for the right patient at the right time and location. Indeed, conventional pulmonary drug delivery devices still have poor efficiencies (<25%) for delivering drugs to the lung tumor sites. Major portions of the aggressive medicine deposit on healthy tissue, which causes severe side effects and induces extra health care expenses. Therefore, a new targeted pulmonary drug delivery method is proposed and evaluated using the Computational Fluid-Particle Dynamics (CFPD) method to achieve the lobe-specific delivery. By controlling the release position and velocity of the drug particles at the mouth inlet, drug deposition efficiency (DE) in a designated lobe can be increased up to 90%. Intersubject variability has also been investigated using the noninvasive in silico tool. Results indicate that the glottis constriction ratio is a key factor to influence the effectiveness of the purposed targeted drug delivery method. Although lobe-specific pulmonary drug delivery can be realized, the actuation flow rate must be lower than 2 L/min, and the glottis constriction ratio has a significant impact on the effectiveness of the targeting method. Also, a design idea using e-cigarette as the prototype is proposed as the next-generation inhaler to accommodate the operational flexibility restrictions.
APA, Harvard, Vancouver, ISO, and other styles
9

Sutopo, Hadi, and Ridha Sefina Samosir. "Mobile Multimedia Stop Drugs Tutorial Development." In Proceedings of the 3rd International Conference on Creative Media, Design and Technology (REKA 2018). Paris, France: Atlantis Press, 2018. http://dx.doi.org/10.2991/reka-18.2018.78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zarandi, Marjan Molavi, Rosaire Mongrain, and Olivier F. Bertrand. "Modeling Drug Eluting Stents for Coronary Artery Bifurcation Considering Non-Newtonian Effects." In ASME 2010 3rd Joint US-European Fluids Engineering Summer Meeting collocated with 8th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2010. http://dx.doi.org/10.1115/fedsm-icnmm2010-31190.

Full text
Abstract:
Drug Eluting Stents (DES) are commonly used for the treatment of stenotic arteries. Restenosis can be treated by delivering anti-thrombotic and anti-proliferative drugs to the arterial wall. The main mechanism of the drug eluting stent is to allow diffusion of the drug from the coating on the stent, into the arterial wall over a prolonged period of time. Investigation of blood flow hemodynamics and shear stress are of great importance in understanding the transport of drugs through the circulatory systems and predicting the performance of drug eluting stents. While drug eluting stent effectively reduces restenosis rate, the conventional drug eluting stent should be optimized to be used in the bifurcation stenting. Various flow patterns due to specific designs of drug eluting stent influence drug delivery. Numerical simulation techniques are appropriate approaches to study such phenomena which can be used to optimize the design of drug eluting stents for bifurcations. In this paper, the complexity of drug eluting stent function in the bifurcation is presented by employing computational fluid dynamics analysis for various stent strut designs. Drug transportation through the lumen and determination of local drug concentrations in arterial wall is carried out for both Newtonian and non-Newtonian flow conditions. It is, to the author’s best knowledge, the first investigation of drug dispersion in arterial bifurcation considering the effects of both the blood rheological properties and stent strut design.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Drugs design"

1

Taufer, Michela, Sandeep Patel, and Narayan Ganesan. Computer-Aided Design of Drugs on Emerging Hybrid High Performance Computers. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada607433.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Cheng, and Yue Yang. Impact of adaptive design on reducing the duration of clinical trials in rare cancers: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0081.

Full text
Abstract:
Review question / Objective: Whether the application of adaptive design in clinical trials of rare cancers can shorten the duration of clinical trials? Condition being studied: Currently, the development of innovative drug products (InMPs) for rare cancers faces many challenges, including the difficulty of enrolling sufficient numbers of patients from small and heterogeneous patient populations for clinical trials, and the significant risks of high financial investment, long development times and potential failure from a pharmaceutical company's perspective for rare cancer drugs due to limited knowledge of the natural history of the disease. Therefore, alternative approaches to clinical trial design are needed to conduct cost-effective, well-controlled analyses that can assess treatment effects in small, heterogeneous populations within shorter time frames. Adaptive trials, on the other hand, may be an effective solution to this problem. Adaptive clinical trials are designed to accelerate the clinical trial process by making predefined adjustments to key parameters through data accumulated at predefined time points during the trial without compromising the integrity and validity of the results.This study aims to examine the value of adaptive design in reducing the duration of clinical trials in rare cancers and encourage their wider implementation.
APA, Harvard, Vancouver, ISO, and other styles
3

Matthews, Lisa, Guanming Wu, Robin Haw, Timothy Brunson, Nasim Sanati, Solomon Shorser, Deidre Beavers, Patrick Conley, Lincoln Stein, and Peter D'Eustachio. Illuminating Dark Proteins using Reactome Pathways. Reactome, October 2022. http://dx.doi.org/10.3180/poster/20221027matthews.

Full text
Abstract:
Diseases are often the consequence of proteins or protein complexes that are non-functional or that function improperly. An active area of research has focused on the identification of molecules that can interact with defective proteins and restore their function. While 22% percent of human proteins are estimated to be druggable, less than fifteen percent are targeted by FDA-approved drugs, and the vast majority of untargeted proteins are understudied or so-called "dark" proteins. Elucidation of the function of these dark proteins, particularly those in commonly drug-targeted protein families, may offer therapeutic opportunities for many diseases. Reactome is the most comprehensive, open-access pathway knowledgebase covering 2585 pathways and including 14246 reactions, 11088 proteins, 13984 complexes, and 1093 drugs. Placing dark proteins in the context of Reactome pathways provides a framework of reference for these proteins facilitating the generation of hypotheses for experimental biologists to develop targeted experiments, unravel the potential functions of these proteins, and then design drugs to manipulate them. To this end, we have trained a random forest with 106 protein/gene pairwise features collected from multiple resources to predict functional interactions between dark proteins and proteins annotated in Reactome and then developed three scores to measure the interactions between dark proteins and Reactome pathways based on enrichment analysis and fuzzy logic simulations. Literature evidence via manual checking and systematic NLP-based analysis support predicted interacting pathways for dark proteins. To visualize dark proteins in the context of Reactome pathways, we have also developed a new website, idg.reactome.org, by extending the Reactome web application with new features illustrating these proteins together with tissue-specific protein and gene expression levels and drug interactions.
APA, Harvard, Vancouver, ISO, and other styles
4

Boaden, Dr Bill. Syringe labelling in anaesthesia and critical care areas: review 2022. Association of Anaesthetists of Great Britain and Ireland, September 2022. http://dx.doi.org/10.21466/g.sliaacc.2022.

Full text
Abstract:
This document replaces the Association of Anaesthetists’ previous guidance1 on this topic, following the publication of BS ISO 26825:2020. BS ISO 26825:2020 is the second edition of the standard for user-applied labels for syringes containing drugs used in anaesthesia. It technically revises, cancels and replaces the 2008 first edition. It gives requirements for labels attached to syringes so that the contents can be identified during anaesthesia and covers the colour, size, design and general properties of the label and the typographical characteristics of the wording for the drug name. Its purpose is solely for use in anaesthesia and as such covers a range of core drug groups. It is acknowledged that these labels may find a use in other critical care areas. The main technical reason for the revision of BS ISO 26825 was to improve the colour, size and design of the labels. Several labels were revised to take account of comments made regarding their clarity and possibility of confusion in use.
APA, Harvard, Vancouver, ISO, and other styles
5

Biazus-Dalcin, Camila, Louise Marryat, Sarah Gray, Andrea Mohan, Senga Robertson-Albertyn, Sreekanth Thekkumkara, Hazel Booth, et al. My data: an animated film, co-produced with people who use drugs. University of Dundee, 2023. http://dx.doi.org/10.20933/100001299.

Full text
Abstract:
This video was co-produced with people on their drug use recovery journey to explore the perceptions of administrative data use for research and to share this information with the wider community. This work was led by members of the Substance Use Research Group (SURG), School of Health Sciences, University of Dundee. This project was funded by Research Data Scotland (RDS), https://www.researchdata.scot/ A film by: Craig Glencross, David Hood, Jade Renton, Maxine Thomson, Ryan Westwood, Stewart Bernard, Sarah Hulin, Robert Doig, Ashley McMaihin and everyone at Restoration Fife who shared their views and experiences. Research team and collaborators: Camila Biazus Dalcin (Co-PI) and Louise Marryat (Co-PI) Sarah Gray (Co-I) Andrea Mohan (Co-I) Senga Robertson-Albertyn (Co-I) Sreekanth Thekkumkara (Co-I) Hazel Booth (Co-I) Calum Hoggitt (Mental Health Nursing Student) Kay McMahon (Receptionist Fife Campus) Graham Ogilvie (Conference in pictures – Ogilvie Design) Andrew Low (Artist) We appreciate the collaboration and support provided by all Restoration Fife staff involved in this project. Special thanks to Jade Whyte and Vanessa Hamilton.
APA, Harvard, Vancouver, ISO, and other styles
6

Dong, Chengda, Hongshuo Shi, Zhaojun Yan, and Jianmin Liu. Quality of Evidence Supporting the Role of Nonsteroidal Anti-inflammatory Drugs for the Treatment of Anxious Depression: A protocol for Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0029.

Full text
Abstract:
Review question / Objective: Population: the participants had anxious depression diagnosed according to any authoritative diagnostic criteria, no restrictions on sex, race, age, onset time, or the source of cases. Intervention: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including oral and injectable NSAIDs. Comparison: conventional antidepressants. Outcome：effective rate, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Treatment Emergent Symptom Scale, potential gastrointestinal and neurological adverse events, etc. Study design: Randomized controlled trial. Information sources: Literature searches were conducted in the Cochrane Library, PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure (CNKI), SinoMed, Chongqing VIP. Gray literature including conference proceedings, fund application report by hand, and other possible sources including citation searching and websites.
APA, Harvard, Vancouver, ISO, and other styles
7

Anderson, Burt, Richard Heller, Ed Turos, and Mark Mclaughlin. Drug Discovery, Design and Delivery. Fort Belvoir, VA: Defense Technical Information Center, June 2012. http://dx.doi.org/10.21236/ada563482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marks, James. Structural Basis of EGFR Dimerization for Drug Design. Fort Belvoir, VA: Defense Technical Information Center, September 2000. http://dx.doi.org/10.21236/ada396569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Menlove, H. O., D. B. Beddingfield, and M. M. Pickrell. Passive neutron design study for 200-L waste drums. Office of Scientific and Technical Information (OSTI), September 1997. http://dx.doi.org/10.2172/534520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rodgers, L. A. ,. ICP Kaiser Hanford. Shielding design evaluations of concrete-lined drums for RH-Truwaste. Office of Scientific and Technical Information (OSTI), June 1996. http://dx.doi.org/10.2172/657964.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drugs design' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography